[email protected]

国际临床研究杂志

International Journal of Clinical Research

您当前位置：首页 > 精选文章

International Journal of Clinical Research. 2023; 7: (8) ; 10.12208/j.ijcr.20231289 .

Research progress on the relationship between Intestinal microecological imbalance and the occurrenceand development of Nonalcoholic fatty liver disease
肠道微生态失衡与非酒精性脂肪肝发生发展的相关研究进展

作者： 张秋心, 郑盛 *

大理大学第二附属医院消化内科 云南昆明

*通讯作者： 郑盛,单位：大理大学第二附属医院消化内科 云南昆明；

引用本文: 张秋心, 郑盛 肠道微生态失衡与非酒精性脂肪肝发生发展的相关研究进展[J]. 国际临床研究杂志, 2023; 7: (8) : 16-21.
Published: 2023/8/20 17:58:22

摘要

肠道微生态（Intestinal microecology， IM）是由肠道微生物群、肠道黏膜和肠道免疫系统组成的极其复杂的生态系统。非酒精性脂肪肝（nonalcoholic fatty liver disease，NAFLD）是指在没有过量饮酒（男性每天≥30g，女性每天≥20g）或其他慢性肝病的情况下，存在超过5%的相关肝细胞出现脂肪变性，包括一系列广泛的表现，从单纯的脂肪变性到非酒精性脂肪性肝炎（Nonalcoholic steatohepatitis，NASH）、纤维化，最终发展为肝硬化甚至肝细胞癌。目前多项研究表明肠道微生态失衡与非酒精性脂肪肝的发生发展有着密切联系，本文就肠道微生态失衡与非酒精性脂肪肝的发生发展相关机制进行综述，并总结肠道微生态对NAFLD的治疗性预期，以期对NAFLD的预防和治疗提供依据。

关键词： 肠道微生态；非酒精性脂肪肝；非酒精性脂肪性肝炎；肝硬化；肝癌

Abstract

Intestinal microecology,(IM) is an extremely complex ecosystem composed of intestinal microflora, intestinal mucosa and intestinal immune system. Non-alcoholic fatty liver disease (NAFLD) means that more than 5% of related liver cells have steatosis without excessive drinking (male ≥30g per day, female ≥20g per day) or other chronic liver diseases, including a wide range of manifestations, ranging from simple steatosis to Nonalcoholic steatohepatitis (NASH), fibrosis and so on. At present, many studies show that intestinal microecological imbalance is closely related to the occurrence and development of nonalcoholic fatty liver disease. This paper reviews the mechanism of intestinal microecological imbalance and the occurrence and development of nonalcoholic fatty liver disease, and summarizes the therapeutic expectation of intestinal microecology on NAFLD, in order to provide basis for the prevention and treatment of NAFLD.

Key words： Intestinal microecology nonalcoholic; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Liver cirrhosis; Hepatoma

参考文献 References

[1] Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2023;13:1087260.

[2] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402.

[3] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209.

[4] Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020;158(7):1851-1864.

[5] Wong VW, Wong GL, Chan RS, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018;69(6): 1349-1356.

[6] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212-2224. 

[7] Duell PB, Welty FK, Miller M, et al. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168-e185.

[8] Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2021;27(2):221-235.

[9] Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol. 2019;71(2):313-322. 

[10] Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond). 2018;18(3):245-250.

[11] Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?. Gastroenterology. 2020;158(7):1881-1898.

[12] Zhou B, Yuan Y, Zhang S, et al. Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal Tract. Front Immunol. 2020;11:575. 

[13] Fu Q, Song T, Ma X, Cui J. Research progress on the relationship between intestinal microecology and intestinal bowel disease. Animal Model Exp Med. 2022;5(4): 297-310.

[14] Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020; 113(12):2019-2040.

[15] Gomaa EZ. Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020; 113(12):2019-2040. 

[16] Noureddin M, Mato JM, Lu SC. Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine. Exp Biol Med (Maywood). 2015;240(6):809-820.

[17] Pierantonelli I, Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation. 2019;103(1):e1-e13. 

[18] Wang XJ, Malhi H. Nonalcoholic Fatty Liver Disease. Ann Intern Med. 2018;169(9):ITC65-ITC80.  

[19] Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038-1048.

[20] Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49(2):197-211.

[21] Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1.

[22] Doulberis M, Srivastava S, Polyzos SA, et al. Active Helicobacter pylori Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients. J Clin Med. 2020;9(4):933. 

[23] Petrescu M, Vlaicu SI, Ciumărnean L, et al. Chronic Inflammation-A Link between Nonalcoholic Fatty Liver Disease (NAFLD) and Dysfunctional Adipose Tissue. Medicina (Kaunas). 2022;58(5):641.

[24] Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020;158(7):1999-2014.e1.

[25] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202-209.

[26] Polyzos SA, Mantzoros CS. Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD). Metabolism. 2020;111S:154318.

[27] Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82-97. 

[28] Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab. 2021;50:101122.

[29] Makri E, Goulas A, Polyzos SA. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. Arch Med Res. 2021;52(1):25-37. 

[30] Milosevic I, Vujovic A, Barac A, et al. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int J Mol Sci. 2019;20(2):395.

[31] Brandl K, Schnabl B. Intestinal microbiota and nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2017;33(3):128-133.

[32] Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13(7):412-425.

[33] Peng JH, Leng J, Tian HJ, et al. Geniposide and Chlorogenic Acid Combination Ameliorates Non-alcoholic Steatohepatitis Involving the Protection on the Gut Barrier Function in Mouse Induced by High-Fat Diet. Front Pharmacol. 2018;9:1399. 

[34] Li F, Sun G, Wang Z, et al. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients. Sci China Life Sci. 2018;61(7):770-778. 

[35] Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17(5):279-297.

[36] Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci. 2019;76(8):1541-1558.

[37] Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019;11(2):e9302.

[38] Hartmann P, Hochrath K, Horvath A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology. 2018;67(6):2150-2166. 

[39] Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?. Gastroenterology. 2020;158(7):1881-1898.

[40] Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72(3):558-577.

[41] Kwok R, Choi KC, Wong GL, et al. Screening diabetic patients for non-alcoholic fattyliver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65(8):1359-1368. 

[42] Tokushige K, Ikejima K, Ono M, et al. Evidence-based clinical practice guidelines fornonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. J Gastroenterol. 2021;56(11):951-963.

[43] Tsuchida T, Lee YA, Fujiwara N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer [published correction appears in J Hepatol. 2018 Oct;69(4):988]. J Hepatol. 2018;69(2):385-395.

[44] Isaacs S. Nonalcoholic Fatty Liver Disease. Endocrinol Metab Clin North Am. 2023;52(1):149-164.

[45] Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53(3): 362 -376. 

[46] Esler WP, Bence KK. Metabolic Targets in Nonalcoholic Fatty Liver Disease. Cell MolGastroenterol Hepatol. 2019;8(2):247-267.

[47] Chi Y, Lin Y, Lu Y, Huang Q, Ye G, Dong S. Gut microbiota dysbiosis correlates with a low-dose PCB126-induced dyslipidemia and non-alcoholic fatty liver disease. Sci Total Environ. 2019;653:274-282.

[48] Liu J, Kong L, Shao M, et al. Seabuckthorn polysaccharide combined with astragalus polysaccharide ameliorate alcoholic fatty liver by regulating intestinal flora. Front Endocrinol(Lausanne). 2022;13:1018557. 

[49] Filipovic B, Lukic S, Mijac D, et al. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2021;22(24):13219. 

[50] Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci. 2021;22(12):6485.

[51] Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed). 2021;26(2):206-237.